|
Case
|
Age (y)
|
Gender
|
Smoking
|
Histology
|
EGFR mutation
|
PFS to 1st TKI
|
TKI sequence
|
Interval from 1st and 2nd
|
Chemo. after 1st
|
PS
|
Response
|
PFS to 2nd TKI
|
OS from 2nd TKI
|
|---|
|
1
|
50
|
F
|
Current
|
Ad
|
NA
|
9.8
|
G→E
|
7.9
|
CBDCA+GEM
|
1
|
PD
|
0.9
|
13.1
|
|
2
|
46
|
F
|
Never
|
Ad
|
NA
|
11.8
|
G→G
|
4.5
|
DOC
|
1
|
PR
|
6.4
|
24.6
|
|
3
|
58
|
F
|
Ex
|
Ad
|
19 deletion
|
38.4
|
G→G
|
2.8
|
DOC
|
1
|
SD
|
7.3
|
24.1
|
|
4
|
70
|
F
|
Never
|
Sq
|
NA
|
10.2
|
G→E
|
12.8
|
GEM
|
1
|
SD
|
1.7
|
4.3
|
|
5
|
60
|
F
|
Never
|
Ad
|
NA
|
13
|
G→G
|
5.4
|
GEM
|
1
|
PD
|
1.6
|
2.1
|
|
6
|
63
|
F
|
Never
|
Ad
|
NA
|
7.4
|
G→E
|
2.6
|
-
|
3
|
SD
|
3.6
|
7.8
|
|
7
|
52
|
M
|
Never
|
Ad
|
L858R
|
5.8
|
G→E
|
1
|
-
|
4
|
SD
|
6.4
|
6.4
|
|
8
|
51
|
M
|
Current
|
Ad
|
NA
|
4.3
|
G→E
|
1.6
|
AMR
|
3
|
PD
|
0.6
|
0.9
|
|
9
|
61
|
F
|
Never
|
Ad
|
NA
|
8.5
|
G→E
|
2.3
|
VNR
|
3
|
SD
|
2.9
|
4
|
|
10
|
53
|
F
|
Never
|
Ad
|
NA
|
12.9
|
G→E
|
0
|
-
|
4
|
SD
|
6.2
|
7.3
|
|
11
|
54
|
M
|
Current
|
Ad
|
19 deletion
|
3.8
|
G→E
|
7.3
|
VNR
|
1
|
SD
|
3.2
|
5
|
- PFS, progression-free survival; TKI, tyrosine kinase inhibitor; PS, performance status; OS, overall survival; F, female; M, male; Ex, ex-smoker; Ad, adenocarcinoma; Sq, squamous cell carcinoma; G, gefitinib; E, erlotinib; CBDCA, carboplatin; GEM, gemcitabine; DOC, docetaxel; AMR, amrubicin; VNR, vinorelbine; PR, partial response; SD, stable disease; PD, progressive disease.
